Australian Cancer Research Foundation Department of Cancer Biology and Therapeutics, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
Department of Immunology and Infectious Disease, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
J Infect Dis. 2021 Jan 4;223(1):10-14. doi: 10.1093/infdis/jiaa623.
Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay-based approach that combines data about immunoglobulin G responses to both the nucleocapsid and spike receptor binding domain antigens, we show that excellent sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (95% Confidence Interval, 0-1.15%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.
对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）抗体的血清流行率的估计受到检测灵敏度和特异性不足的阻碍。我们使用基于酶联免疫吸附测定的方法，结合针对核衣壳和刺突受体结合域抗原的免疫球蛋白 G 反应数据，表明可以达到出色的灵敏度和特异性。我们使用该检测方法评估了澳大利亚一组择期手术患者中的病毒特异性抗体频率，并估计澳大利亚的血清流行率为 0.28%（95%置信区间，0-1.15%）。这些数据证实了 2020 年 7 月之前澳大利亚 SARS-CoV-2 的传播水平较低，并验证了我们检测方法的特异性。
